Epigenomics AG / DE000A37FT41
15.02.2024 - 10:00:10Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet
| Epigenomics AG / Key word(s): Personnel 15.02.2024 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024. Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024. For the time being, Mr. Hummel's appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024. Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011. As a tax advisor and specialist consultant for international tax law, he is an expert in the field of corporate transactions, international tax law and group structures. Dr. Helge Lubenow, Chairwoman of the Supervisory Board: “We are very much looking forward to working with Mr. Hummel and his extensive expertise, which will enrich our Board.” Contact: Company Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: contact@epigenomics.com Investor Relations IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: ir@epigenomics.com Note on forward-looking statements This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise. 15.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
| Language: | English |
| Company: | Epigenomics AG |
| Bertha-Benz-Straße 5 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 24345-0 |
| Fax: | +49 30 24345-555 |
| E-mail: | ir@epigenomics.com |
| Internet: | www.epigenomics.com |
| ISIN: | DE000A37FT41 |
| WKN: | A37FT4 |
| Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1838167 |
| End of News | EQS News Service |
| |
